Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
See Latest ArticlesClinical and therapeutic aspects of osteoporosis
European Journal of Radiology, 09/16/09
Compston J – Because of their broad spectrum of demonstrated anti–fracture efficacy, alendronate, risedronate, zoledronate and strontium ranelate are generally considered as front–line options for most women. The optimum duration of treatment has not been established but re–evaluation of risk and the need for continued therapy after 5 years of treatment may be appropriate. Compliance and persistence with long–term treatment is poor but may be improved by less frequent dosing regimens.
Today in Menopausal Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/11/09
Sponsor
Article Search
Sponsor